VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Kiniksa Pharmaceuticals International Executive Compensation (FY25)

KNSA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Sanj Patel
Latest say-on-pay support
=
May 29, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Kiniksa Pharmaceuticals International

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 29, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Kiniksa Pharmaceuticals International brief$500Get the executive brief
Velarion Intel, one year, every company
478 figures on this page: 472 cited to the filing that reported them, 6 calculated from figures it prints. See the citations

More on Kiniksa Pharmaceuticals International

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sanj Patel: $7,129,792 → $10,782,661 (51.2% higher)
CEO pay ratio: 25:1 → 35:1 (40.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Kiniksa Pharmaceuticals International's chief executive and what were they paid?
Sanj Patel was paid $10,782,661 in total compensation as Chief Executive Officer and Chairman of the Board for fiscal 2025. Compared with the $7,129,792 reported for fiscal 2024, Patel's total was 51.2% higher.
What was Kiniksa Pharmaceuticals International's say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 97.3% support at the meeting held May 29, 2026.
Which companies are in Kiniksa Pharmaceuticals International's peer group?
The disclosed peer group names Acadia Pharmaceuticals, Agios Pharmaceuticals, Amicus Therapeutics, Apellis Pharmaceuticals and Ardelyx, among others.
What is Kiniksa Pharmaceuticals International's chief executive pay ratio?
The company reported a chief executive pay ratio of 35:1 for fiscal 2025, against median employee compensation of $310,707.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sanj Patel
Chief Executive Officer and Chairman of the Board
◇—◇◇◇—◇◇
John Paolini
Senior Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Eben Tessari
Senior Vice President and Chief Operating Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sanj Patel
Chief Executive Officer and Chairman of the Board
◇—◇◇◇—◇◇
John Paolini
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Mark Ragosa
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Eben Tessari
Executive Vice President and Chief Operating Officer
◇—◇◇◇—◇◇
Ross Moat
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sanj Patel
Chief Executive Officer and Chairman of the Board
◇—◇◇◇—◇◇
John Paolini
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Eben Tessari
Executive Vice President and Chief Operating Officer
◇—◇◇◇—◇◇
Ross Moat
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Mark Ragosa
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sanj Patel
Chief Executive Officer and Chairman of the Board
◇—◇◇◇—◇◇
Ross Moat
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
John Paolini
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Eben Tessari
Executive Vice President and Chief Operating Officer
◇—◇◇◇—◇◇
Mark Ragosa
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Eben TessariPSU◇◇◇—◇——
Eben TessariRSU◇——◇——◇
Eben TessariOPTION◇——◇—◇—
Eben TessariRSU◇——◇——◇
Eben TessariPSU◇◇◇—◇—◇
Eben TessariOPTION◇——◇—◇◇
Eben TessariOPTION◇——◇—◇◇
John F. PaoliniOPTION◇——◇—◇—
John F. PaoliniPSU◇◇◇—◇——
John F. PaoliniOPTION◇——◇—◇◇
John F. PaoliniOPTION◇——◇—◇◇
John F. PaoliniRSU◇——◇——◇
John F. PaoliniRSU◇——◇——◇
John F. PaoliniPSU◇◇◇—◇—◇
Mark RagosaOPTION◇——◇—◇—
Mark RagosaPSU◇◇◇—◇——
Mark RagosaRSU◇——◇——◇
Mark RagosaRSU◇——◇——◇
Mark RagosaOPTION◇——◇—◇◇
Mark RagosaPSU◇◇◇—◇—◇
Mark RagosaOPTION◇——◇—◇◇
Ross MoatOPTION◇——◇—◇—
Ross MoatPSU◇◇◇—◇——
Ross MoatOPTION◇——◇—◇◇
Ross MoatRSU◇——◇——◇
Ross MoatRSU◇——◇——◇
Ross MoatPSU◇◇◇—◇—◇
Ross MoatOPTION◇——◇—◇◇
Sanj K. PatelPSU◇◇◇—◇—◇
Sanj K. PatelRSU◇——◇——◇
Sanj K. PatelRSU◇——◇——◇
Sanj K. PatelOPTION◇——◇—◇◇
Sanj K. PatelOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Sanj PatelOption◇—◇08/31/2035
Option◇—◇03/31/2035
Option◇—◇08/31/2034
Option◇—◇03/31/2034
PSU◇◇——
Option◇—◇08/31/2033
Option◇—◇03/31/2033
Option◇—◇08/31/2032
RSU◇◇——
PSU◇◇——
Option◇—◇04/06/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Ross MoatOption◇—◇08/31/2035
Option◇—◇03/31/2035
Option◇—◇08/31/2034
Option◇—◇03/31/2034
PSU◇◇——
Option◇—◇08/31/2033
Option◇—◇03/31/2033
Option◇—◇08/31/2032
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇04/06/2032
RSU◇◇——
RSU◇◇——
Eben TessariOption◇—◇8/31/2035
Option◇—◇3/31/2035
Option◇—◇8/31/2034
Option◇—◇3/31/2034
PSU◇◇——
Option◇—◇8/31/2033
Option◇—◇3/31/2033
Option◇—◇8/31/2032
RSU◇◇——
PSU◇◇——
Option◇—◇4/6/2032
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
John PaoliniOption◇—◇08/31/2035
Option◇—◇03/31/2035
Option◇—◇08/31/2034
Option◇—◇03/31/2034
PSU◇◇——
Option◇—◇08/31/2033
Option◇—◇03/31/2033
Option◇—◇08/31/2032
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇04/06/2032
PSU◇◇——
RSU◇◇——
RSU◇◇——
Mark RagosaOption◇—◇08/31/2035
Option◇—◇03/31/2035
Option◇—◇08/31/2034
Option◇—◇03/31/2034
Option◇—◇08/31/2033
PSU◇◇——
Option◇—◇03/31/2033
RSU◇◇——
Option◇—◇08/31/2032
RSU◇◇——
Option◇—◇04/06/2032
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Eben Tessari
Executive Vice President and Chief Operating Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
John Paolini
Executive Vice President and Chief Medical Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Mark Ragosa
Senior Vice President and Chief Financial Officer · Employment agreement
Benefits continuation on change in control◇
Benefits continuation◇
Sanj Patel
Chief Executive Officer and Chairman of the Board · Terms as described in the company’s compensation discussion
Severance multiple◇
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard S. Levy
◇◇◇——◇◇
Felix J. Baker
Lead independent director
◇◇◇———◇
Barry D. Quart
◇◇◇———◇
Thomas R. Malley
◇◇◇———◇
Kimberly J. Popovits
◇◇◇———◇
Stephen R. Biggar
◇◇◇———◇
Tracey L. McCain
◇◇◇———◇
G. Bradley Cole
◇◇◇———◇
M. Cantey Boyd
◇◇◇———◇
Sanj K. Patel served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Rsus/Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Acadia Pharmaceuticals ACAD
  • Agios Pharmaceuticals AGIO
  • Amicus Therapeutics FOLD
  • Apellis Pharmaceuticals APLS
  • Ardelyx ARDX
  • BioCryst Pharmaceuticals BCRX
  • BridgeBio Pharma BBIO
  • Corcept Therapeutics CORT
  • Harmony Biosciences Holdings HRMY
  • Ironwood Pharmaceuticals IRWD
  • MacroGenics MGNX
  • Rhythm Pharmaceuticals RYTM
  • Sage Therapeutics SAGE
  • Supernus Pharmaceuticals SUPN
  • Travere Therapeutics TVTX
  • Vericel VCEL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 29, 2026=◇◇◇
2024June 3, 2025=◇◇◇
2023June 5, 2024=◇◇◇
2022June 6, 2023=◇◇◇
2021June 29, 2022=◇◇◇
2020June 29, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Sanj Patel (Chief Executive Officer and Chairman of the Board), FY2025 total compensation $10,782,661 (base salary $943,129) [exec_comp, SEC accession 0001104659-26-044410, filed 2026-04-16]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Kiniksa Pharmaceuticals International files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Kiniksa Pharmaceuticals International disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Kiniksa Pharmaceuticals International sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Kiniksa Pharmaceuticals International's disclosed peer group is defensible, who names Kiniksa Pharmaceuticals International back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
478 figures on this page: 472 cited to the filing that reported them, 6 calculated from figures it prints.
472 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001730430-26-000029
    Proposal 8 - To approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.
  2. 0001104659-26-044410
    2025 Grants of Plan-Based Awards Table · CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · and 4 more sections
  3. 0001104659-25-055990
    Proposal 10 – To approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.
  4. 0001104659-25-036852
    Summary Compensation Table
  5. 0001558370-25-001505
    Exhibit
  6. 0001104659-24-068694
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001104659-24-050621
    Summary Compensation Table
  8. 0001104659-23-068966
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001104659-23-051434
    2022 Summary Compensation Table
  10. 0001104659-22-076309
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001104659-21-089476
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kiniksa Pharmaceuticals International executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KNSA (accessed 2026).
Short form: data: Velarion

The paid brief for Kiniksa Pharmaceuticals International

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kiniksa Pharmaceuticals International and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Kiniksa Pharmaceuticals International discloses

The companies named in KNSA's own disclosed peer group.

Acadia PharmaceuticalsAgios PharmaceuticalsAmicus TherapeuticsApellis PharmaceuticalsArdelyxBioCryst PharmaceuticalsBridgeBio PharmaCorcept TherapeuticsHarmony Biosciences HoldingsIronwood PharmaceuticalsMacroGenicsRhythm PharmaceuticalsSage TherapeuticsSupernus PharmaceuticalsTravere TherapeuticsVericel

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy